Abstract 3887
Background
Tumour-tissue biopsy testing is the standard of care (SOC) to assess RAS mutation in mCRC pts. However, the analysis of circulating cell-free DNA (cfDNA) has the added advantage of being able to evidence genetic tumour heterogeneity. We explored the correlation of the RAS mutational status assessed in plasma samples with first-line (1L) treatment outcomes in SOC RAS wild type (wt) mCRC pts.
Methods
Prospective, observational, multi-centre study in mCRC pts with RASwt according to tumour-tissue biopsy and treated following standard clinical practice. Plasma samples were collected before starting 1L treatment and sent to Sysmex Inostics GmbH for BEAMing analysis. The lower threshold limit was a mutant allele fraction (MAF) ≥ 0.02%. Tumour response (TR) was evaluated approximately every 3 months based on RECIST criteria.
Results
119 pts were included (61% male; median age: 65 y). 113 received chemotherapy (CT) + anti-EGFR, 4 CT + anti-VEGF and 2 CT alone. Overall response rate (ORR) was 68.1% (95%CI: 58.9-76.3) for all pts and 75% (95%CI: 65.8-82.8) in the108 pts with TR data. In pts treated with panitumumab (n = 92), the most homogeneous group, 76.1% (n = 70) presented left-sided tumours and 19.6% (n = 18) right-sided; overall ORR was 78.3% (95%CI: 68.4-86.2); 81.4% (95%CI: 70.3-89.7) for left and 72.2% (95%CI: 46.5-90.3) for right-sided pts. ORR in the panitumumab subgroup according to RAS mutational status analysed in cfDNA for the three MAF (cut-offs) considered is presented in the table.Table: 546P
| ORR (not confirmed) % (95% CI) | ORR (not confirmed) % (95% CI) | Odds Ratio (95% CI); P-value* | |
|---|---|---|---|
| Mutant allele fraction, cut-off (n) | RASwt | RASmt | |
| ≥1% (90 wt/2 mt) | 78.9 (69.0 – 86.8) | 50.0 (1.3 - 98.7) | 3.7 (0.2 – 62.6) 0.389 |
| ≥0.1% (87 wt/5 mt) | 79.3 (69.3 – 87.3) | 60.0 (14.7 - 94.7) | 2.6 (0.4 – 16.5) 0.297 |
| ≥0.02% (80 wt/12 mt) | 80.0 (69.6- 88.1) | 66.7 (34.9-90.1) | 2.0 (0.5 – 7.5) 0.285 |
Fisher Test; CI=confidence interval; ORR: Overall Response Rate.
Conclusions
A high ORR was observed in pts treated with panitumumab independently of the localization. ORR in panitumumab treated patients tends to be higher in plasma RASwt. ORR in pts with plasma RASmt increases when a lower MAF cut-off is used. Further investigation is needed to find the optimal clinical cut-off. Study supported by Amgen.
Clinical trial identification
Legal entity responsible for the study
Amgen.
Funding
Amgen.
Editorial Acknowledgement
Disclosure
P. García Alfonso: Consulting fees: Amgen, Bristol, Merck, Sanofi, Roche, Bayer, Servier. M. Valladares-Ayerbes: Research grants: Roche; Consulting fees: Amgen, Roche, Merck, Sanofi, Servier. J.M. Viéitez: Research grants: Amgen, Roche; Consulting fees: Amgen, Roche, Servier, Shire, Bayer. J.J. Cruz Hernandez: Consulting fees: Amgen, Merck, Roche, BMS. A. Lloansí Vila: Full time employee, stocks: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract